Portal de Periódicos da CAPES

Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity–focused ultrasound focal therapy for localized prostate cancer

2016; Elsevier BV; Volume: 35; Issue: 1 Linguagem: Inglês

10.1016/j.urolonc.2016.07.015

1873-2496

Louise Dickinson, Hashim U. Ahmed, Richard G. Hindley, Neil McCartan, Alex Freeman, Clare Allen, Mark Emberton, Alex Kirkham,

MRI in cancer diagnosis

Focal therapy for localized prostate cancer has the potential for oncological control without the side effects of radical therapies. However, there is currently no validated method for monitoring treatment success. We assessed the diagnostic performance of prostate-specific antigen (PSA) parameters and MRI compared to histological outcomes following focal therapy. Patients from 3 Ethics Review Board approved prospective studies of focal high intensity–focused ultrasound (HIFU) (Sonablate 500) for localized prostate cancer (T1c–T3a, Gleason grade≤4+3, and PSA≤20). Post-HIFU PSA nadir, 6-month PSA, PSA density, and early ( 3 mm or any Gleason 4 tumor. Early and late MRI performed better than PSA measurements in the detection of residual tumor after focal therapy.